Cholinesterázy a cholinesterázové inhibitory

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216275%3A25310%2F08%3A00007777" target="_blank" >RIV/00216275:25310/08:00007777 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Cholinesterases and Cholinesterase Inhibitors

Popis výsledku v původním jazyce

Alzheimer´s disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimer´s disease has progressed in the past ten years from the use of psychotropic medications for sedationto the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimer´s disease and is approved by the US Food and Drug Administration for Alzheimer´s disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimer´s disease.

Název v anglickém jazyce

Cholinesterases and Cholinesterase Inhibitors

Popis výsledku anglicky

Alzheimer´s disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimer´s disease has progressed in the past ten years from the use of psychotropic medications for sedationto the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimer´s disease and is approved by the US Food and Drug Administration for Alzheimer´s disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimer´s disease.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2008

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Enzyme Inhibition

ISSN

1573-4080

e-ISSN

—

Svazek periodika

4

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

12

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—